All In Biotech

Drug Trial Radar · NCT05512377

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

99

Actual

Start

Dec 13, 2022

Primary completion

Sep 25, 2025

Study completion Sep 25, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Participants may continue to take BI 907828 as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check the size of the tumour and whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Pancreatic Neoplasms
  • Solid Tumors
  • Biliary Tract Cancer
  • Lung Neoplasms
  • Bladder Cancer

Interventions

  • BrigimadlinDrug

    Patients received brigimadlin 45 mg orally on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response (OR)Time frame: From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.

Locations

60 sites in 16 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center

    Mobile, Alabama

  • University of Arizona

    Tucson, Arizona

  • University of Southern California

    Los Angeles, California

  • Stanford Cancer Institute

    Palo Alto, California

  • Providence Medical Foundation-Santa Rosa -69764

    Santa Rosa, California

  • Rocky Mountain Cancer Centers-Lone Tree-69498

    Lone Tree, Colorado

  • Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky

  • University of Michigan

    Ann Arbor, Michigan

  • Nebraska Cancer Specialists-Omaha-69066

    Omaha, Nebraska

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island

    Mineola, New York

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Oncology Associates of Oregon, PC

    Eugene, Oregon

  • Oregon Health and Sciences University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Prince of Wales Hospital-Randwick-66496

    Randwick, New South Wales, Australia

  • ICON-South Brisbane-69267

    South Brisbane, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • Ordensklinikum Linz GmbH - Barmherzige Schwestern

    Linz, Austria

  • LK Wiener Neustadt

    Wiener Neustadt, Austria

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • CTR Georges-François Leclerc

    Dijon, France

  • Institut Gustave Roussy

    Villejuif, France

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Krankenhaus Nordwest, Frankfurt

    Frankfurt, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Klinikum der Universität München AÖR

    München, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • National Cancer Center Hospital East

    Chiba, Kashiwa, Japan

  • Kanagawa Cancer Center

    Kanagawa, Yokohama, Japan

  • Tohoku University Hospital

    Miyagi, Sendai, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, Japan

  • Japanese Foundation for Cancer Research

    Tokyo, Koto-ku, Japan

  • Yamaguchi University Hospital

    Yamaguchi, Ube, Japan

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.